Skip to main content
Journal cover image

Predictors of complete responses with denileukin diftitox in cutaneous T-cell lymphoma.

Publication ,  Journal Article
Foss, F; Duvic, M; Olsen, EA
Published in: Am J Hematol
July 2011

Duke Scholars

Published In

Am J Hematol

DOI

EISSN

1096-8652

Publication Date

July 2011

Volume

86

Issue

7

Start / End Page

627 / 630

Location

United States

Related Subject Headings

  • Time Factors
  • Skin Neoplasms
  • Recurrence
  • Recombinant Fusion Proteins
  • Randomized Controlled Trials as Topic
  • Lymphoma, T-Cell, Cutaneous
  • Interleukin-2
  • Immunology
  • Diphtheria Toxin
  • Clinical Trials, Phase III as Topic
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Foss, F., Duvic, M., & Olsen, E. A. (2011). Predictors of complete responses with denileukin diftitox in cutaneous T-cell lymphoma. Am J Hematol, 86(7), 627–630. https://doi.org/10.1002/ajh.22039
Foss, Francine, Madeleine Duvic, and Elise A. Olsen. “Predictors of complete responses with denileukin diftitox in cutaneous T-cell lymphoma.Am J Hematol 86, no. 7 (July 2011): 627–30. https://doi.org/10.1002/ajh.22039.
Foss F, Duvic M, Olsen EA. Predictors of complete responses with denileukin diftitox in cutaneous T-cell lymphoma. Am J Hematol. 2011 Jul;86(7):627–30.
Foss, Francine, et al. “Predictors of complete responses with denileukin diftitox in cutaneous T-cell lymphoma.Am J Hematol, vol. 86, no. 7, July 2011, pp. 627–30. Pubmed, doi:10.1002/ajh.22039.
Foss F, Duvic M, Olsen EA. Predictors of complete responses with denileukin diftitox in cutaneous T-cell lymphoma. Am J Hematol. 2011 Jul;86(7):627–630.
Journal cover image

Published In

Am J Hematol

DOI

EISSN

1096-8652

Publication Date

July 2011

Volume

86

Issue

7

Start / End Page

627 / 630

Location

United States

Related Subject Headings

  • Time Factors
  • Skin Neoplasms
  • Recurrence
  • Recombinant Fusion Proteins
  • Randomized Controlled Trials as Topic
  • Lymphoma, T-Cell, Cutaneous
  • Interleukin-2
  • Immunology
  • Diphtheria Toxin
  • Clinical Trials, Phase III as Topic